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ABSTRACT: Natural products and their derivatives continue to be wellsprings of nascent therapeutic potential. However,
many laboratories have limited resources for biological evaluation, leaving their previously isolated or synthesized compounds
largely or completely untested. To address this issue, the Canvass library of natural products was assembled, in collaboration
with academic and industry researchers, for quantitative high-throughput screening (qHTS) across a diverse set of cell-based
and biochemical assays. Characterization of the library in terms of physicochemical properties, structural diversity, and similarity
to compounds in publicly available libraries indicates that the Canvass library contains many structural elements in common
with approved drugs. The assay data generated were analyzed using a variety of quality control metrics, and the resultant assay
profiles were explored using statistical methods, such as clustering and compound promiscuity analyses. Individual compounds
were then sorted by structural class and activity profiles. Differential behavior based on these classifications, as well as
noteworthy activities, are outlined herein. One such highlight is the activity of (−)-2(S)-cathafoline, which was found to
stabilize calcium levels in the endoplasmic reticulum. The workflow described here illustrates a pilot effort to broadly survey the
biological potential of natural products by utilizing the power of automation and high-throughput screening.
■ INTRODUCTION
Throughout history, nature has served as our primary source of
medicines and continues to be one of the richest sources of new
therapeutics. Either directly or as inspiration, natural products
account for 50% to 70% of all small-molecule pharmaceutical
agents currently in clinical use.1 While their influence has been
most profound in the treatment of infectious diseases and
cancer, natural products have also found utility in other ther-
apeutic areas such as pain, inflammation, and cardiovascular dis-
orders. Yet, many pharmaceutical companies have diminished or
abandoned natural products research throughout recent decades
for a variety of reasons, ranging from the promise of emerging
technologies (e.g., combinatorial chemistry), to concerns about
international regulations of access to natural products and their
sources.2 In parallel, decreases in funding agency support for
natural-products-related research have contributed to this con-
traction. However, within the same time period, natural com-
pounds still continue to be both a significant source and point of
inspiration for new medicines.1
Despite this dichotomy, the pendulum is swinging back
toward natural products within both industry and academia.
New screening libraries are being designed to incorporate key
features of natural products, including scaffold diversity and
stereochemistry.2 Strategic prefractionation methods have also
facilitated high-throughput screening of natural product
extracts.2,3 Genome mining with the goal of discovering
“hidden” natural products withinmicrobial genomes4 has fostered
a great deal of excitement, and is the foundational approach of a
number of pharmaceutical companies. The academic sector has
also begun to see a recovery in the funding climate, as reflected in
the creation of the Center for High-Throughput Functional
Annotation of Natural Products (HiFAN).5 HiFAN is a
collaborative, international, multi-institute center established
to determine the mechanism of action of natural products and
botanicals, with the intention of making platform technologies
and data available community-wide. Together, these and other
developments bode well for the renewed interest in nature as a
rich resource for biologically relevant chemical matter.
While this resurgence has significant potential, especially to
address the imminent threat of antibiotic resistance,6 we
hypothesize that therapeutic opportunities for natural products
across other disease indications have been underexplored. All
too often, isolation scientists and synthetic chemists in academic
laboratories isolate or synthesize natural products and test them
against a single representative cancer cell line or bacterial strain,
or in some instances, never test their compounds in any
biological assay at all, missing out entirely on the potential to
discover a valuable, new therapeutic. Do storage freezers in
laboratories engaged in natural product synthesis throughout
the world contain the next advancements in human health?
Toward realizing the potential of purified natural products, we
established the Canvass natural product screening pilot initiative
to provide the scientific community with a mechanism to
evaluate the biological activities of natural products in a diversity
of in vitro assays.
With the Canvass pilot program, we set out to crowd-source a
diverse set of purified natural products by inviting academic
investigators and companies to submit their natural products to
the National Center for Advancing Translational Sciences
(NCATS). Upon assembly, the Canvass library was compared to
other relevant, well-studied chemical libraries. We then sought to
broadly explore, or “canvass”, the library’s biological activity in an
assortment of robust assays using quantitative high-throughput
screening (qHTS).7 Due to the broad scope of disease-relevant
mechanisms investigated by NCATS, we were able to screen the
library against a wide range of assays. The resulting data set from
50 different assays was then systematically analyzed to identify
overall trends and specific natural products with interesting
biological activities. Project teams at NCATS further investigated
the activities of several compounds using established workflows,
and the full data set was made available through the Canvass
website (https://tripod.nih.gov/canvass).
■ RESULTS
Canvass Library. The Canvass library of 346 natural
products was assembled through a broad solicitation of both
the academic and private sectors via the Canvass website. The
pure (>85% purity by liquid chromatography/mass spectrom-
etry [LC/MS]) compounds were submitted by 45 academic
laboratories or companies around the world. We collected pure
natural products, rather than natural product extracts, to circum-
vent deconvolution and structure elucidation due to time and
resource limitations. The library was formatted into 1536-well
plates and evaluated in 50 assays by qHTS in an 11-point
concentration series.7,8 We manually classified9 the Canvass
compounds using a set of 12 well-known structural classes, the
distribution of which is summarized in Figure 1a.
Physicochemical Property Distributions. To ascertain
the similarity of the Canvass library to existing drug collections,
we analyzed and compared the structural features and physi-
cochemical properties of the compound collection to publicly
available compound collections known to contain druglike com-
pounds or natural products. We first examined the physico-
chemical properties of the library in comparison to three well-
known small-molecule libraries: the DrugBank Approved Drugs
(2073 compounds, database version: 2.0.9),10 the ChEMBL11
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natural product set (1921 compounds, database version:
ChEMBL 23), and a random subset of 3000 molecules from
the Life Chemicals Diversity Set of 50K molecules (LC50K,
50 240 compounds). Selecting a subset of the LC50K library was
necessary to reduce the dominance of the chemical space of such
a large and diverse library. These libraries, spanned by com-
pounds representing the entry-points and end-points of the drug
discovery pipeline, helped us evaluate how the Canvass collec-
tion fits within drug discovery space. Specifically, we used the
collections ofChEMBLnatural products and LC50Kmolecules to
represent the entry-points of drug discovery space. The ChEMBL
collection generally represented natural products which histori-
cally have served as a rich source of drugs or starting points in
lead-optimization efforts, while the LC50K molecules exempli-
fied the engineered libraries of diverse compounds characterized
by desirable properties for lead-discovery purposes. Meanwhile,
since the DrugBank set covers the majority of approved small-
molecule drugs, it represented the end-points space.
We computed seven physicochemical properties: molecular
weight (MW), H-bond acceptor (HBA) and H-bond donor
(HBD) counts, XLogP,12 the number of rotatable bonds
(RotB), the plane of best fit (PBF),13 and fraction of rotatable
bonds (flexibility).14 While the first five are relevant in a drug
discovery setting, the PBF and flexibility descriptors characterize
the three-dimensionality of the molecules. As shown by Meyers
et al.,15 many synthetic scaffolds tend toward flatness, and there
Figure 1. (a) Distribution of structural classes within the Canvass library. (b) Physicochemical properties of chemical libraries; MW = molecular
weight, HBA =H-bond acceptor, HBD =H-bond donor, RotB = number of rotatable bonds, PBF = plane of best fit. (c) Chemical space overlap of the
Canvass library with three other libraries in a 1024D fingerprint space reduced to two dimensions using tSNE. ECFP-6 fingerprints were computed
using the CDK; tSNE = t-distributed stochastic neighbor embedding, ECFP-6 = extended connectivity fingerprint of diameter = 6, CDK = Chemistry
Development Kit.
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has been increasing interest to enhance the three-dimensionality
of molecules in screening libraries.16 Figure 1b summarizes the
distribution of these properties for the Canvass collection versus
those of the other libraries. While the medians of the properties
are well-aligned between the Canvass and LC50K collections, it
should be noted that Canvass compounds represent a more
diverse physicochemical space. The accordance of median
property values toward the ChEMBL and DrugBank collections
shows a mixed picture. There is an almost perfect split in the
number of cases where the Canvass physicochemical properties
are more closely aligned with either the ChEMBL or DrugBank
collections. Surprisingly, the distribution of PBF is similar
between the four libraries.15
Chemical Space Overlap.We next examined the chemical
space overlap of the Canvass library with the three comparator
libraries. We considered two distinct chemical spaces: the physi-
cochemical 7-dimensional descriptor space defined above, and a
1024-dimensional fingerprint space emphasizing structural
features. In both cases, we computed a reduced 2-dimensional
(2D) space using t-distributed stochastic neighbor embedding
(tSNE).17 The results for the physicochemical space analysis are
presented in the Supporting Information (see Figure S1). In the
physicochemical space, the Canvass library is very similar to the
other libraries, even though they may not be specifically natural-
product-like, which is in line with the property distributions
summarized in Figure 1b. We quantified the overlap between
pairs of libraries using Thornton’s separability index (S),18
resulting in the following values: 0.81, 0.82, and 0.89 for Canvass
versus the ChEMBL natural products, DrugBank, and the
LC50K subset, respectively. A larger index represents a larger
separation in terms of likeness. These indices support previous
observations regarding physicochemical property distributions
that Canvass compounds are well-aligned with the other libraries
in terms of their physicochemical properties. As expected, the
closest set to Canvass in physicochemical space is the ChEMBL
natural products set.
We then computed 1024-bit ECFP-619 fingerprints using the
Chemistry Development Kit (CDK)20 for all compounds
and examined the overlap in fingerprint space (Figure 1c).
We observed that the embedding of Canvass compounds in this
chemical space shows a resemblance to that of the ChEMBL
natural products, as might be expected. Further, the chemical
space occupied by Canvass and the DrugBank compounds
shows a significant overlap. The quantitated overlap (using the
separability index) reflects similar observations that we made
regarding the physicochemical space, only, in this chemical
space, Canvass overlaps to the highest degree with theDrugBank
library (0.93), followed by ChEMBL natural product (0.95) and
the LC50K (0.99) libraries. While this is somewhat unexpected,
it may indicate that the Canvass library contains a number of
structural elements in common with approved drugs.
Summary of the Assay Panel. The Canvass library was
screened in qHTS format with 11-point dose−response against
50 assays covering a variety of readouts, modalities, and targets
(either specific protein targets or biological processes) in both
cell-based and biochemical assays. The bulk (33) of the assays
focused on viability (e.g., cytotoxicity, cell proliferation, or
membrane integrity), while 11 assays probed specific pathways
(e.g., hypoxia-inducible factor 1-alpha [HIF1] signaling, or cal-
ciummodulation), and the remaining 6 assays were designed for
specific biochemical targets (e.g., mutant isocitrate dehydrogen-
ase 1 [mIDH1] or ATPase family AAA domain-containing
protein 5 [ATAD5]). All cell-based assays were measured at a
single end-point, with the exception of the apoptosis assays using
Caspase-Glo, which were measured at three time-points (12, 18,
and 24 h). This screen generated over 210 000 data points.
Though it is worth noting that, while we ran 50 individual assays,
this number includes counter-screens associated with other
assays. An example is the secreted endoplasmic reticulum calcium-
monitoring proteins (SERCaMP) assay designed to detect
endoplasmic reticulum (ER) calcium dysfunction.21 The primary
assay identifies compounds that prevent depletion of the ER
calcium store and is accompanied by secretion and viability
counter-assays, each of which is designed to eliminate false
positives from the primary assay.
A variety of quality control (QC) metrics22 were computed
for each assay (focusing on the primary readout only) including
Z′-factor,23 signal-to-background (S/B), and the coefficient of
variation (CV). QC measure values associated with plates of
Z′≤−10 were treated as outliers and accordingly excluded from
the analysis. Figure 2a−c summarizes the Z′, S/B, and CV for all
assays, grouped by their type (pathway, target, and viability).
In general, assay performance22 was good (0 < Z′ ≤ 0.5) to
excellent (Z′ > 0.5) for all the assays in the panel, with a few
exceptions. For instance, in the caspase-HEK293 apoptosis
assay, the control compound (doxorubicin) did not elicit suffi-
cient signal, which necessitated normalization using the maxi-
mum value from the sample wells. As a result, the Z′ is not
relevant for this particular assay. For assays with multiple
readouts, we report only the median QC measure for the main
readout. Except for the apoptosis assays, the viability assays
tended to exhibit slightly better performance across all metrics
than the other two assay classes (Figure 2d). A separate plot was
made for better visibility of QCmeasure values for assays of Z′≥
0 and of SB < 60 (see Figure S2).
Clustering Assays. Several features stand out from a pair-
wise correlation matrix of a vector representation of the assays
(Figure 3, see the Experimental Methods section for details).
At a high level, four clusters of assays are apparent. The largest
cluster is composed mainly of cytotoxicity assays (purple) with
several pathways-specific (green) and one target-specific (red)
assays. The cytotoxicity assays exhibit a negative correlation with
a number of other assays (e.g., apoptotic assays), which can be
largely attributed to the normalization scheme. Agonist assays
have positive normalized areas under the curve (nAUCs),
whereas antagonist assays have negative nAUCs. However, the
observed negative correlations are modest. The second major
cluster is composed of the three target-specific (red), two
pathway and two cytotoxicity assays that exhibit overall poor
correlation with any other. This is likely indicative of the
orthogonal nature of biological or chemical processes captured
by these assays. For instance, counter-assays associated with
different screening technologies, such as AlphaLISA or fluo-
rescence, are poorly correlated with each other, as expected.
However, the diaphorase and redox counter-assays that are also
in this cluster are correlated to some degree as one would expect;
the negative correlation in this case is due to the normalization
schemes. Two smaller clusters are characterized by a high corre-
lation among the associated assays. One cluster includes the
apoptotic assays, membrane integrity, protease, and HIF1
assays. The other cluster is composed of the p53, ATAD5, and
CAR assays. Similar observations can bemade when clustering is
performed with the help of log AC50 and efficacy values of
samples (see Figures S5 and S6). Overall, the screening results in
the Canvass assay panel confirm general expectations based on
the nature of the individual assays.
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Promiscuity Analysis. Promiscuous compounds can pose
challenges in screening campaigns.24 Promiscuity can be due to
assay interference (such as quenching and autofluorescence) or
intractable mechanisms of action, including nonspecific
Figure 2. (a−c) Distribution of median assay quality control measures among the three assay classes (pathway, target, and viability). (d) Summary of
quality control metrics for the Canvass assay panel, characterized as a pathway-based (pink), a target-based (blue), or a viability assay (green). For all
metrics the median values, across all plates run in the assay, are reported.
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reactivity, redox, or aggregation by pan-assay interference
compounds (PAINS),25 and can be evaluated from the hit-
rate among all high-throughput screens run during a given
period.24,26,27 Given that we screened the Canvass library in
50 assays, we characterized the promiscuity of these compounds
based on their nAUC values. We considered the absolute value
of nAUCs and ignored the pharmacological action (inhibitor,
agonist, or antagonist) of the individual compounds. Using this
parameter, we defined a compound as promiscuous using two
rules: (i) the transformed nAUC value falls into the 90th
percentile in a given assay, and (ii) the first condition holds true
for at least 40% of the assays. This rule identified 49 compounds
as promiscuous, and these are summarized in Figure S3
(compounds listed in Table S2). However, given that the
majority of the assays in which these compounds are active are
cytotoxicity assays, rather than target-specific assays, the
commonality of the assay end-points may unfairly emphasize
their promiscuity. A number of these compounds, however, do
appear as hits in target-specific assays (e.g., ATAD5, constitutive
androstane receptor [CAR], SERCaMP), but their activity
could have been driven by toxicity. To identify compounds not
captured by the use of nAUC values, similar promiscuity
analyses were carried out using the log AC50 data and the
absolute value of the efficacy data. For the promiscuity analysis
based on log AC50 data, compounds with a log AC50 value lower
than the 10th percentile were considered, and the analysis did
not reveal additional promiscuous compounds. The promiscuity
analysis of the efficacy data was performed in an analogous
manner to the nAUC analysis, and it revealed 12 additional
promiscuous compounds that might be associated with
cytotoxicity or aggregation at high concentrations (Figure S3).
Figure 3.Heatmap representation of the clustering of the assays, based on the Pearson correlation matrix computed from z-scored compound nAUCs.
Pearson correlation can have a value between −1 and 1, where 0 means no correlation, 1 means completely positively correlated, and −1 means
completely negatively correlated.
ACS Central Science Research Article
DOI: 10.1021/acscentsci.8b00747
ACS Cent. Sci. 2018, 4, 1727−1741
1733
Cytotoxicity Panel Overview.We profiled the cytotoxicity
of the Canvass library against a collection of 16 cell lines
representing a range of malignancies. The primary motivation
for assessing cell killing was the well-known contribution of
natural product sources to the chemotherapeutic pharmaco-
poeia. A secondary goal was to identify cytotoxic compounds
that may produce artifacts in other cell-based assays performed
as part of the library profiling. Sensitivity varied across all cell
lines (Figure 4a), though some compounds demonstrated near
pan-activity: herboxidiene (NCGC00488492), strophanthidin
3-O-β-glucopyranosyl-(1,2)-O-β-diginopyranosyl-(1,4)-O-β-cym-
aropyranosyl-(1,4)-O-β-digitoxopyranoside (NCGC00488465),
and lactimidomycin (NCGC00488635). There was no clear
clustering of sensitivity by tissue-of-origin, although the sensi-
tivity of the canine glioma cell lines G06 and SDT closely
correlated. Of the compounds in the library, 49% demonstrated
Figure 4. (a) Comparison of the cytotoxicity of each compound (rows) in 16 cancer cell lines (columns). The heatmap was generated based on the
area under the dose−response curve (AUC). Dark red indicates a more potent and efficacious compound. (b) AUC correlation plot of KB-8-5-11 vs
KB-3-1. AUC for each Canvass compound is represented by a dot with prospective P-gp substrates highlighted (pink) above the unity line (dashed).
(c) Dose−response activity of (+)-chamaecypanone C, a prospective P-gp substrate identified in the Canvass library screen. This compound showed
selective killing against KB-3-1 (black), resistance in KB-8-5-11 (gray), and reversal of resistance to levels approaching that of KB-3-1 in KB-8-5-11 +
1 μM tariquidar (pink).
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class 1 or 2 curves7 with maximum response over 50% against at
least one cell line.
Natural product cytotoxins are susceptible to efflux by
multidrug-resistance transporters. To identify P-glycoprotein
(P-gp) substrates, we tested compounds against a P-gp over-
expressing cell line, KB-8-5-11, and its nonexpressing parental
counterpart, KB-3-1. Inhibition of P-gp reverses resistance to
P-gp substrates. KB-8-5-11 cells cotreated with 1 μM tariquidar
(KB-8-5-11 + tariquidar), a known P-gp inhibitor, were also
tested to confirm the P-gp substrates. P-gp substrates demon-
strate reduced cell killing against KB-8-5-11 cells, and greater activity
against the parent KB-3-1 cell line. Comparison of activity (AUC)
against the two cell lines revealed a small number of compounds less
active against the P-gp-expressing cell line (above the unity line,
Figure 4b), and most compounds did not demonstrate significant
cytotoxicity (clustered at the origin, Figure 4b). Confirmation
retesting revealed 4 substrates among 40 compounds demonstrating
cytotoxicity (pink spheres, Figure 4b): batzelladine D
(NCGC00488661), (+)-chamaecypanone C (NCGC00488556,
Figure 4c), apicidin (NCGC00165733, Figure S4), and an iso-
migrastatin derivative (NCGC00488640). Concentration−
response curves show that KB 8-5-11 cells were resistant to
cell killing, but were sensitized by the P-gp inhibitor tariquidar.
Apoptotic Behavior.The Canvass assay panel enables us to
probe a wide variety of pharmacological responses, but at fixed
time-points. The inclusion of the apoptosis assays (measured
using Caspase-Glo) read at three time-points (12, 18, and 24 h)
allowed us to explore the apoptotic response to the compounds
over time. The majority of the 346 Canvass compounds did not
induce apoptosis at any of the time-points (just 33 compounds
exhibited an active dose−response at one or more time-points),
and only 19 compounds induced caspase activity in a dose−
response manner at all three time-points in any of the two assays
(Figure 5a). In general, these 19 compounds did not exhibit high
potencies, with the exception of 15-deoxygoyazensolide
(NCGC00488496) (see Figure 5b). Nevertheless, we catego-
rized the observed activities in relation to the two cell lines
(HPAF-II and HEK293) for compounds based on the detected
maximal response signal (“Max. Data”). This schema gave rise to
four categories. Compounds characterized by “high” apoptotic
activity in HPAF-II but “low” in HEK293 assays may have
implications for biasing apoptosis induction toward cancer as
opposed to normal cells. Three compounds were found that fall
under this group of interest (NCGC00488600,NCGC00488498,
NCGC00488506).
We also examined the correlation between the 19 compounds
inducing apoptosis at all three time-points and their activities in
the remaining 27 viability assays. We computed the fraction of
assays in which each of these compounds exhibited an active curve
class. These values ranged from0.18 (chatancin,NCGC00488505)
Figure 5.Compounds that induce apoptosis: (a) 19 compounds were identified as able to induce apoptosis as they were active at all three time-points
in the apoptosis assay. The graph shows the fraction of the 27 non-caspase viability assays in which these 19 compounds are active. Individual points are
colored by the maximum reading (Max. Data) observed across the two caspase assays (cell lines: HPAF-II and HEK293). The observed maximum
readings were grouped based on quartiles (low−less than equal to median; and high−greater than median). Inactive samples were assigned to category
“low” for clarity. (b) Curve fit parameters for 15-Deoxygoyazensolide the most potent compound in the Canvass library exhibiting apoptotic activity at
all three time-points in any of the two cell lines (HEK293, HPAF-II) and its structure; nAUC = normalized area under the curve.
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to 0.93 ((+)-cryptocaryol A, NCGC00488500). The values for all
compounds are summarized in Figure 5a, where we overlaid the
maximum efficacy observed in the caspase assays for each
compound. In general, compounds that strongly induce
apoptosis tended to also show cytotoxic behavior across most
of the viability assays.
Activity Highlights. Nuclear receptors (NRs) are proteins
that regulate physiological homeostasis, metabolism, and
development.28 One crucial NR is the constitutive androstane
receptor (CAR, NR1I3), which regulates many drug metaboliz-
ing enzymes and transporters while also playing an essential role in
energy homeostasis.29 In this study, we screened the Canvass library
of natural products for activation/deactivation of CAR employing a
double stable reporter cell line (HepG2-CYP2B6-hCAR).30
To identify activators, we added 0.75 μM 1-(2-chlorophenyl-
methylpropyl)-3-isoquinoline-carboxamide (PK11195),31 a known
CAR inhibitor, while adding 50 nM 6-(4-chlorophenyl)imidazo-
[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime
(CITCO, a known CAR activator),32 to identify any deacti-
vators in the Canvass collection.
Piperine (NCGC00094872), the pungent component of black
and long peppers, and (+)-herboxidiene (NCGC00488492) were
identified as strong, potent activators ofCARwith efficacies of 63%
and 609%(relative toCITCO) andEC50 values of 4.9 and 0.12μM,
respectively (Figure 6a). Sintokamide A (NCGC00488482)
produced a very strong deactivation of CAR with an efficacy of
102% (relative to PK11195) and an IC50 of 9.3 μM (Figure 6b).
This compound also did not induce cytotoxicity, as a multi-
plexed system was used in the same well to identify lumi-
nescence and viability concurrently. All three of these com-
pounds, however, also elicited a very strong response for
pregnane X receptor (PXR, NR1I2) activation. However, a
cross-talk exists between PXR and CAR, complicating the
deconvolution of each receptor’s independent contributions.
Therefore, further studies are necessary to more accurately
identify the specific NR-related behavior of these compounds
both in vitro and in vivo.
Canvass was also screened for activity on the endoplasmic
reticulum (ER) calcium store. Small molecules that stabilize ER
calcium are of interest for diverse pathologies, including cardio-
vascular diseases and diabetes.33 The secreted ER calcium-
monitoring protein (SERCaMP) assay30 was utilized to assess
ER calcium homeostasis by measuring a reporter protein that is
secreted in response to ER calcium depletion.21 SH-SY5Y
neuroblastoma cells were treated with thapsigargin to deplete
the ER calcium store, and compounds that reduced SERCaMP
secretion, indicative of ER calcium stabilization, were iden-
tified. The screen was run in duplicate on separate days, with
30 compounds showing activity in both experiments. False
positives attributable to nonspecific effects on the secretory
pathway or cell viability were identified using a set of counter-
screens, and 17 compounds (57%) were active in one or both
of the counter-screens. The most favorable profile was observed
for (−)-2(S)-cathafoline (NCGC00488578), with an AC50 of
2.8 μM in the SERCaMP assay and no activity in the counter-
screens (Figure 6c), suggesting that the compound stabilizes
ER calcium levels. Analyzing the full activity profile of (−)-2(S)-
cathafoline revealed that it is highly selective for ER calcium
modulation; it was not a hit in any other assays in the panel.
Further studies are underway to examine the effect of this
compound in disease models associated with ER calcium
dysregulation.
Figure 6. (a) Dose−response curves for the CAR activator (NCGC00094872) identified in the Canvass library. The stable cell line treated with
compound and CITCO for 24 h in 1536-well plates was treated with ONE-Glo, and the luminescence intensity was calculated (black). The efficacies
were compared to the CITCO positive controls, and the viability was also detected using fluorescence in the same well (pink). Data are expressed as
mean± standard error of the mean for triplicate assays. (b) Dose−response curves for the CAR deactivator (NCGC00488482) using same method in
part a, except cells were cotreated with PK11195 instead of CITCO, and PK11195 was used as positive controls. (c) 2(S)-Cathafoline is active in the
secreted ER calcium-monitoring protein (SERCaMP) assay, indicating the compound stabilizes ER calcium. Activity was examined in the primary
SERCaMP assay (pink), a secretion counter-screen (gray), and a viability counter-screen (black). Mean activity ± SD (n = 3) is shown.
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■ DISCUSSION
With generous contributions from laboratories throughout the
world, we assembled a diverse set of 346 natural products for
biological evaluation. Comparison of the Canvass library to
three other chemical libraries (DrugBank, LC50K, and
ChEMBL natural products) revealed that all four inhabit very
similar physicochemical property space, though the LC50K
subset tends to be focused with respect to most parameters.
Given that DrugBank is a drug library and LC50K is designed for
lead discovery purposes, their overlap with ChEMBL natural
products and the Canvass libraries supports the observation that
natural products are the origins for many drugs. Considering
both the physicochemical space and fingerprint structural
comparisons, Canvass compounds are most similar to druglike
molecules in the DrugBank library. Despite some degree of
structural overlap with the ChEMBL natural product set, it is
evident that the Canvass set samples novel structural space
compared to the other three libraries. Though the Canvass
compounds comprised of natural products, their properties are
more aligned with drugs than with the ChEMBL natural
products, earning them a unique position among chemical
collections. This suggests that the Canvass library is a good
complement to the ChEMBL natural product set for drug
discovery purposes.
The Canvass natural product library was screened in 50
distinct assays to broadly canvass the pharmacological activity of
the compounds. The assortment of assays utilized in this pilot
study cover a wide biological scope, and they were selected
because they have been successfully implemented for qHTS at
NCATS. Cytotoxicity was heavily emphasized given the history of
natural products as anticancer and anti-infective agents. Targets
with unique pharmacological potential, including CAR and
Nrf2/ARE, were also examined. The balance of the screen
probed developing pharmacological mechanisms in other areas
such as inflammation (inflammasome) and cardiovascular as
well as rare diseases (SERCaMP).
Beyond the facets highlighted through the analyses, not-
able activities also emerged for a small subset of compounds.
We discovered three natural products that modulate the nuclear
receptor CAR. Interestingly, the molecules highlighted above
are structurally quite distinct from one another; one of them,
piperine, is a component of the dietary spice pepper, and its
observed activity has brought to light an unappreciated pharma-
cological impact of this widely consumed natural product.
The strategic utility of specific counter-screens facilitated the
identification of selectively-active compounds, as exemplified
by (−)-2(S)-cathafoline in the SERCaMP assay. The calcium-
stabilizing effect of this molecule is significant, especially
given that cathafoline was highly selective across our panel; it
was not active in any other Canvass assays. Though it is a
member of a large family of indole alkaloids, little was known
about the biological activity of cathafoline prior to this Canvass
study. Fortuitously, the Garg laboratory’s prior total synthesis
campaign34 provided access to synthetic cathafoline, which,
when submitted in response to our call for natural products,
enabled the discovery of cathafoline’s promising in vitro activity.
Studies are underway to elucidate the biological target of
cathafoline and to realize the full potential of its calcium modu-
latory effects.
Investigations of potent natural products continue to reveal
key biological targets with therapeutic relevance. For example,
the isolation and biological evaluation of peptides isolated from
viper snake venom helped bring to light the importance of the
angiotensin converting enzyme (ACE) in regulating blood
pressure. This discovery inspired the design of the drug captopril
for the treatment of hypertension.35 There is no doubt that
natural products will continue to impact the numerous unmet
medical needs of both ubiquitous illnesses and rare diseases
alike, especially as we have only just begun to understand new
and developing areas of disease biology, such as the human
microbiome. It is our hope that screening natural product
libraries for a wide range of biological activities, as with the
Canvass pilot program, will accelerate the development of
therapeutics in many disease areas. The Canvass pilot program
serves as an example of how to successfully leverage resources
and expertise throughout the scientific community for the
evaluation of natural products in drug discovery, and it will serve
as a framework for larger scale investigations in the future.
■ EXPERIMENTAL METHODS
The Canvass library of 346 natural products was assembled
through a broad solicitation of both the academic and private
sectors via the Canvass website, with heavy emphasis on natural
product isolation and total synthesis laboratories. To streamline
the pursuit of biological discoveries and minimize deconvolu-
tion, only pure natural products were accepted. The NCATS
Compound Management team provided our collaborators with
tared, barcoded vials for natural product submissions to facilitate
both the receipt and processing of samples. Quality control
(QC) for purity >85% was managed in two ways: by requiring
the cosubmission by PIs of recent analyses of submitted natural
products utilizing either LC/MS or 1H NMR, and subsequently
upon receipt of samples, NCATS performing LC/MS analyses
of all submissions. By implementing two QC checks, we mini-
mized QC failures for natural products which are unstable to our
standard LC/MS QC protocols. In total, 45 PIs or institutions
submitted a sum of 346 natural products to assemble the
Canvass library, which was subsequently evaluated in 50 whole-
cell or biochemical assays. This library continues to serve as a
valuable resource in screening campaigns following the work
described herein.
Data generated by the Canvass program has been made
available to our collaborators via the website, located at https://
tripod.nih.gov/canvass/. The website provides open access to
both general and detailed overviews of the program as a whole,
as well as a subset of the assays which were planned at the outset,
and a portal for questions and answers. By registering,
collaborators’ accounts allowed access to secure and private
interfaces to expedite compound submissions and to simplify
data browsing. Importantly, data generated for a given set of
compound submissions were initially only made accessible to
the submitters. The application provides the traditional tabular
view of compound activities, with a variety of visualizations to
provide high-level summaries of activity in the assay panel, along
with detailed views for individual compounds. With this
publication, the full data set presented herein is now available
at the Canvass website (https://tripod.nih.gov/canvass/).
■ DATA SETS AND COMPUTATIONAL METHODS
Chemical Libraries. The Canvass library consists of 346
compounds that can be described as natural products. To better
characterize the chemical space represented by these com-
pounds, we included three additional chemical libraries in
our analysis: the DrugBank Approved Drugs (2073 compounds,
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database version: 2.0.9), the ChEMBL natural products (1921
compounds, database version: ChEMBL 23), and the Life
Chemicals Diversity Set of 50K molecules (LC50K, 50 240
compounds). The LC50K collection was included to provide a
baseline for the comparison of molecular properties. To this end,
a subset consisting of 3000 molecules was sampled randomly
from the LC50K collection and used in subsequent analyses.
Chemical libraries were subjected to the same standardization
scheme as part of a KNIME workflow including community
nodes originating from CDK cheminformatics suites.36−39
Standardization steps involved keeping only the largest
component of compounds.
qHTS Data Processing Pipeline.While the data processing
details for individual assays can be found in their respective
references, we briefly outline the processing pipeline here. Plate
data were normalized to the per-plate positive and negative
controls, and dose−response curves were fitted using a grid-
based algorithm.40,41 Dose−response curves were then assigned
a curve class (see Seethala and Zhang40,6 for more detailed
definitions of curve classes), which is a heuristic classification
that allows us to easily identify good quality versus poor quality
dose−response curves. To assign one of seven possible classes,
the curve is evaluated in terms of features like asymptote
definition, the R2 of the curve fit, and efficacy. Furthermore, for
assays measuring an increase in signal (e.g., agonist assays),
curve classes are positive, and for those measuring a decrease in
signal (e.g., inhibitor or antagonist assays), curve classes are
negative. Broadly, we consider curve classes of 1.1, 1.2, 2.1, and
2.2 (and the corresponding negative values) as good quality
active dose−responses, curve class of 4 as inactive (i.e., no dose
response), and all others as inconclusive dose−responses.
We only deviated from this classification in the case of Caspase
assays, where good quality active dose−responses curves were
considered those that are associated with a curve class value
different from 4.
AUC Computation. In the Canvass assays, the more potent
and efficacious a compound is, the larger its absolute area under
the curve (AUC) value. Moreover, the sign of the AUC reflects
the pharmacological action of a compound (e.g., inhibitors can
be distinguished from activators). It should be noted that
automatically generated raw AUC values can be misleading in
certain cases. For the case of an inhibitory dose−response curve,
which starts in a positive response range, the absolute AUC can
be small due to the nature of numerical integration. A similarly
misleading absolute AUC value is obtained for activation dose−
response curves, which start in the negative response range. Such
anomalies are typically the result of noisy assay data. To remedy
such cases, we found it necessary to transform the raw AUC
values to better reflect the magnitude of biological responses
independent of whether the curve exhibits negative or positive
response values (due to the plate normalization scheme).
Accordingly, in the case of inhibition curves, the maximal y-value
of a curve is subtracted from all y-values. In an analogous
manner, the minimal y-value was subtracted from the y-values of
activation curves. The resultant normalized AUC values are
denoted by nAUC to distinguish them from raw AUC values.
Assay Clustering. To cluster the assays, we first represented
each assay as a 346-element vector of compound nAUC values.
Next, we computed the pairwise Pearson correlation matrix,
which was then clustered using hierarchical clustering with
complete linkage. We also computed clusterings using potency
(setting it to 10 μM for compounds that were inactive in an
assay) and efficacy (Figures S5 and S6).
Descriptor Computation. Physicochemical descriptors
(molecular weight, rotatable bond number, flexibility,14 number
of hydrogen-bond donors/acceptors, clogP,42 TPSA43) and
ECFP6 fingerprints were computed using CDK nodes for
KNIME (version 3.4.2) and processed in R statistical suite
(version 3.4.4) using the fingerprint package.
Library Overlap. Thornton’s separability index (S)18 is a
class separability measure designed to discriminate between
objects from different classes and is commonly used to
characterize the quality of clustering. We applied this measure
to quantify the degree of overlap of two libraries in a predefined
chemical space. S is defined as the fraction of compounds for
which their nearest neighbor is not from the same library as
themselves. Thus, S ranges from 1 (two libraries completely
overlap with each other) to 0 (two libraries have no overlap).
Note that these limits are somewhat dependent on the actual
spatial distribution of compounds in a given chemical space.
Nonetheless, for the purposes of comparing library overlap in a
relative manner, the use of S is sufficient. We implemented
S using R 3.4.4 (code available at https://spotlite.nih.gov/
gzahoranszky/CANVASS.git).
Quantifying 3D-Likeness. The 3D-likeness of compounds
was characterized with the help of a plane of best fit (PBF)13
measure implemented in the RDKit Python Application Pro-
gramming Interface (API) (version 2017.09.1).37 To generate
PBF values, a low energy conformer needs to be generated for
each compound. Low energy conformers were generated by a
KNIME workflow.36−39
Embedding Compounds into 2D Chemical Space. We
defined a physicochemical property space using molecular
weight (MW), H-bond donor count, H-bond acceptor count,
XLogP,12 PBF,13 and flexibility.14 We then employed tSNE
(as implemented in the Rtsne package44 for R) to perform
dimension reduction to 2D,17 using the Euclidean metric for
distance computations. Apart from setting θ = 0.1, all other
parameters were set at their default values. For the case of
fingerprints, we first computed a pairwise similarity matrix using
the Tanimoto metric45,46 and converted it to a distance matrix
(usingD = 1− similarity) for input to the tSNE algorithm, using
the same parameters as used for the physicochemical property
space. The 2D data sets were visualized using R 3.4.4. All work-
flow files, Python source code, computed descriptor, and fingerprint
data are available at https://spotlite.nih.gov/gzahoranszky/
CANVASS.git.
Novelty Assessment of Canvass Compound Struc-
tures. The novelty of the Canvass compounds was assessed on
the basis of the Bemis−Murcko scaffold (BMS)42 of com-
pounds. First, the BMSs of compounds were determined in all
molecular libraries. Next, a unique set of BMSs were derived
library-wise. Finally, the overlap of pairs of unique BMS sets was
quantified relative to the number of unique BMSs in each set. Of
note, the rest of the analyses in this study involved only a random
subset of the LC50K library whereas this assessment was
performed on the entire LC50K library (Table S1).
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